The Food and Drug Administration yesterday said that it will temporarily forgo action against 503A compounding pharmacies that provide to hospitals certain compounded drugs without patient-specific prescriptions.

The agency’s temporary policy outlines specific criteria that pharmacies and hospitals must meet in addition to some conditions established in section 503A of the Federal Food, Drug, and Cosmetic Act.

While the agency recently provided additional guidance for 503B outsourcing facilities, it acknowledged that the flexibilities provided might not be sufficient to meet urgent needs. FDA says this new policy is intended to remain in effect for no longer than the duration of the COVID-19 public health emergency and will be modified as circumstances evolve.

Headline
The Department of Health of Human Services Aug. 21 issued a request for information seeking feedback on immunization categories within the Aug. 10 executive…
Headline
For the 2025-2026 school year, exemptions from one or more vaccines among U.S. kindergartners was at 4.2%, increasing from 3.6% for the previous school year,…
Headline
A study published Aug. 5 by Nature found that COVID-19 infection can reactivate dormant, chronic viruses such as Epstein-Barr and cytomegalovirus. The study…
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…